



GOOD PEOPLE
for GOOD HEALTH

January 7, 2026

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code: 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Ref: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub.: Additional investment in wholly-owned subsidiary

In compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of J. B. Chemicals & Pharmaceuticals Ltd. ('the Company') at its meeting held on January 7, 2026 have approved additional investment of upto ~Rs. 18 crores in its wholly-owned subsidiary Unique Pharmaceutical Laboratories, FZE at Dubai.

Please find enclosed herewith Annexure-I containing the information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard.

The above has been approved by the Board of Directors at its meeting held today, which commenced at 2.22 p.m. and concluded at 2.40 p.m.

We request you to take the above information on record.

Thanking you,

Yours faithfully,

For J. B. Chemicals & Pharmaceuticals Ltd.

**Sandeep Phadnis
Vice President - Secretarial
& Company Secretary**

Registered Office:
J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:
J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com

www.jbpharma.com



GOOD PEOPLE
for GOOD HEALTH

ANNEXURE - I

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

S. No.	Particulars	Disclosure
1.	Name of the target entity, details in brief such as size, turnover etc.	Unique Pharmaceutical Laboratories, FZE ('UPL FZE') – Company's wholly-owned subsidiary at Dubai. Revenue for financial year 2024-25: AED 627,639
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	UPL FZE being a wholly-owned subsidiary of the Company is a related party. Except to the extent of shares held in UPL FZE, the promoter does not have any interest in UPL FZE. The transaction is at arms' length.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The additional investment in equity shares of UPL FZE would be utilized towards operational requirements of UPL FZE.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	NA



GOOD PEOPLE
for GOOD HEALTH

6.	Indicative time period for completion of the acquisition	The investment is likely to be completed within three month. The same may be in one or more tranches.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	100% investment would be in cash.
8.	Cost of acquisition and/or the price at which the shares are acquired	Upto ~Rs. 18 crores
9.	Percentage of shareholding / control acquired and / or number of shares acquired	100% shares of UPL FZE shall be held by the Company and UPL FZE would continue to be wholly-owned subsidiary of the Company.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	UPL FZE, the Company's wholly-owned subsidiary at Dubai, was incorporated on December 10, 2013 under the Jebel Ali Free Zone regulations and is engaged in medicines trading. The revenue for FY 2024-25 was AED 627,639. The Company had no revenue during FY 2023-24 and FY 2022-23.

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com